Drugs / HER2 Tumor Vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05315830 | Mar 2022 → Mar 2023 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | The First Affiliated Hospital of Bengbu Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HER2 Tumor Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05315830 ↗ |
| Modality | Vaccine | “B-cell epitope vaccine” NCT05315830 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT05315830 ↗ |